Q-omics provides the consensus-scored RN7SL619P profile across patient tissues and cancer cell-line models. RN7SL619P expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, RN7SL619P is differentially expressed in 5, with the highest sampling consensus in COAD. Additionally, RN7SL619P RNA expression shows 6,757 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight STAD, and COAD as cancer lineages where RN7SL619P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RN7SL619P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RN7SL619P survival associations across molecular data types. RN7SL619P RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RN7SL619P RNA expression–survival associations across cancer types. High RN7SL619P expression shows unfavorable associations in UCEC, ACC, ESCA and BRCA, but favorable associations in STAD and READ. The STAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify STAD as the clearest survival context for RN7SL619P RNA expression.
This table summarizes RN7SL619P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RN7SL619P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RN7SL619P shows lower tumor expression in KIRC and higher tumor expression in COAD, READ, CHOL and STAD. The COAD box plot shows higher RN7SL619P RNA expression in tumor versus normal tissue (log2 FC = +0.458, t-test p < 0.001).
This table shows molecular features associated with RN7SL619P in patient tissues and cancer cell lines. In patient samples, RN7SL619P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
